UPDATE: Tango Therapeutics Inc. (TNGX) PT Lowered to $16 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Wall St to open higher on oil retreat, tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
March 28, 2022 7:00 AM EDT- TNG908 receives Fast Track designation, expects Phase 1/2 trial to start in 2Q 2022 -
- Pipeline programs progressing throughout 2022 -
- Strong cash position of $485 million expected to support operations into second half of 2024 -
CAMBRIDGE, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2021, and provided business highlights.
... More